Novavax Inc. (NASDAQ:NVAX) has a beta of 1.47. The stock’s Relative Strength Index (RSI) is 40.74, with weekly volatility at 6.12% and ATR at 18.61. The NVAX stock’s 52-week price range has touched low of $14.38 and a $331.68 high. Its shares traded lower over the last trading session, losing -3.91% on 04/07/21. The shares fell to a low of $170.49 before closing at $171.77. Intraday shares traded counted 1.85 million, which was 58.02% higher than its 30-day average trading volume of 4.41M. NVAX’s previous close was $178.76 while the outstanding shares total 65.79M.
Investors have identified the Biotechnology company Novavax Inc. as an interesting stock but before investments are made there, an in-depth look at its trading activities will have to be conducted. The share is trading with a market value of around $12.38 billion, the company now has both obstacles and catalysts that affect them and they came from their mode of operations. With the company affected by events currently, it is a perfect time to analyze the numbers behind the firm in order to come up with a rather realistic picture of what this stock is.
Novavax Inc. (NVAX) Fundamentals that are to be considered.
When analyzing a stock, the first fundamental thing to take into account is the balance sheet. How healthy the balance sheet of a company is will determine if the company will be able to carry out all its financial and non-financial obligations and also keep the faith of its investors. In terms of their assets, the company currently has 1.25 billion total, with 579.67 million as their total liabilities.
Having a look at the company’s valuation, the company is expected to record 32.84 total earnings per share during the next fiscal year. It is very important though to remember that the importance of trend far outweighs that of outlook. This analysis has been great and getting further updates on NVAX sounds very interesting.
Is the stock of NVAX attractive?
In related news, EVP, Chief Commercial Officer, Trizzino John sold 191 shares of the company’s stock in a transaction that recorded on Apr 07. The sale was performed at an average price of 178.03, for a total value of 34,004. As the sale deal closes, the EVP, Chief Commercial Officer, Trizzino John now sold 3,021 shares of the company’s stock, valued at 574,292. Also, EVP, Chief Legal Officer, Herrmann John A III sold 2,894 shares of the company’s stock in a deal that was recorded on Mar 26. The shares were price at an average price of 186.80 per share, with a total market value of 540,609. Following this completion of acquisition, the Director, YOUNG JAMES F now holds 10,000 shares of the company’s stock, valued at 2,282,231. In the last 6 months, insiders have changed their ownership in shares of company stock by 0.20%.
5 out of 5 analysts covering the stock have rated it a Buy, while 0 have maintained a Hold recommendation on Novavax Inc.. 0 analysts has assigned a Sell rating on the NVAX stock. The 12-month mean consensus price target for the company’s shares has been set at $300.75.